Inventor · disambiguated record
Fang Li
Also filed as: LI FANG · Li fang yuan
15 granted patents·20 pending applications·43 citations·filing 1995–2024
89Inventor score
Files withNOVARTIS AG12GORDON JOHN R3GUANGZHOU INSIGHTER BIOTECHNOLOGY CO LTD2LI CHUAN-YUAN2NEW YORK BLOOD CENTER INC2
Top patents by PatentIndex Score
35 records- 0191US8946394B2Conjugate for photodynamic diagnosis or therapy and method for preparing sameNA KUN·Filed 2011·Granted Feb 3, 2015·25 cites·10 claims
- 0283US9663458B2Diaminoguanidine derivatives and application thereof in preparation of animal growth promoters used in feedGUANGZHOU INSIGHTER BIOTECHNOLOGY CO LTD·Filed 2014·Granted May 30, 2017·3 cites·5 claims
- 0378US8609851B2Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereofYANG SHANGJIN·Filed 2009·Granted Dec 17, 2013·5 cites·8 claims
- 0473US8299019B2Uses of modified ELR-CXC chemokine G31P to treat cancerGORDON JOHN R·Filed 2011·Granted Oct 30, 2012·3 cites·9 claims
- 0572US10220038B2Pharmaceutical combinationsNOVARTIS AG·Filed 2018·Granted Mar 5, 2019·1 cites·9 claims
- 0672US7741434B2High-affinity antagonists of ELR-CXC chemokinesGORDON JOHN R·Filed 2008·Granted Jun 22, 2010·1 cites·1 claims
- 0771US7201895B2High-affinity antagonists of ELR-CXC chemokinesUNIV SASKATCHEWAN·Filed 2002·Granted Apr 10, 2007·4 cites·6 claims
- 0864US12036543B2Preparation method of doped ZnO catalyst and synthesis method of higher alcohol using sameUNIV TAIYUAN TECHNOLOGY·Filed 2022·Granted Jul 16, 2024·0 cites·20 claims
- 0962US12053470B2Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitorNOVARTIS AG·Filed 2022·Granted Aug 6, 2024·0 cites·7 claims
- 1062US2025135002A1Compositions for and method of effecting tumor cell deathUNIV DUKE·Filed 2023·Application pending·0 cites
- 1162US2025136689A1Compositions for and methods of treating hematological cancersUNIV DUKE·Filed 2023·Application pending·0 cites
- 1261US2025026763A1Egfr inhibitors and methods of use thereofAllorion Therapeutics Inc·Filed 2024·Application pending·0 cites
- 1361US2015290204A1Combination therapyNOVARTIS AG·Filed 2013·Application pending·0 cites
- 1458US2019160069A1Pharmaceutical combinationsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1555US2016331751A1Pharmaceutical compositionsFERRETTI STEPHANE·Filed 2014·Application pending·0 cites
- 1654US2018015092A1Pharmaceutical combinationsNOVARTIS AG·Filed 2017·Application pending·0 cites
- 1753US11103575B2Immunogenic composition for MERS coronavirus infectionNEW YORK BLOOD CENTER INC·Filed 2017·Granted Aug 31, 2021·0 cites·20 claims
- 1853US2007021593A1High-affinity antagonists of ELR-CXC chemokinesGORDON JOHN R·Filed 2006·Application pending·0 cites
- 1952US2016339023A1Pharmaceutical CombinationsLI FANG·Filed 2014·Application pending·0 cites
- 2052US2017143723A1Pharmaceutical combinationsNOVARTIS AG·Filed 2017·Application pending·0 cites
- 2151US8968702B2Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responsesLI CHUAN-YUAN·Filed 2007·Granted Mar 3, 2015·0 cites·6 claims
- 2250US8940770B2Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereofBEIJING YILING BIOENGINEERING CO LTD·Filed 2013·Granted Jan 27, 2015·0 cites·20 claims
- 2350US2019134033A1Pharmaceutical combinationsNOVARTIS AG·Filed 2018·Application pending·0 cites
- 2449US2015202203A1Method of Treating Gastrointestinal Stromal TumorsMONAHAN JOHN E·Filed 2013·Application pending·0 cites
- 2548US12064476B2Zika virus immunogenic compositionsNEW YORK BLOOD CENTER INC·Filed 2019·Granted Aug 20, 2024·0 cites·17 claims
- 2648US2017157134A1Combination therapyNOVARTIS AG·Filed 2017·Application pending·0 cites
- 2748US2018185365A1Pharmaceutical CombinationsNOVARTIS AG·Filed 2018·Application pending·0 cites
- 2844US2016287605A1Combination therapySHENG QING·Filed 2016·Application pending·0 cites
- 2943US2020085814A1Combination of certinib with an egfr inhibitorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 3042US2019343836A1Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitorNOVARTIS AG·Filed 2018·Application pending·0 cites
- 3141US2015190456A1Use of caspase 3 activity and its inhibitorsLI CHUAN-YUAN·Filed 2012·Application pending·0 cites
- 3241US2014288073A1Method of Treating Gastrointestinal Stromal TumorsNOVARTIS AG·Filed 2012·Application pending·0 cites
- 3337US9938230B2Esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone and application thereof in preparation of animal antibacterial agents and growth promoters used in feedGUANGZHOU INSIGHTER BIOTECHNOLOGY CO LTD·Filed 2014·Granted Apr 10, 2018·0 cites·8 claims
- 3430US5710293AMethod of preparation of ester derivatives of steroidsPOPULATION COUNCIL CENTER FOR·Filed 1995·Granted Jan 20, 1998·1 cites·22 claims
- 3528US2017252335A1Combination of Ceritinib with an EGFR InhibitorPANTANO SERAFINO·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Fang Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →